Free Trial
NASDAQ:DAWN

Day One Biopharmaceuticals Q3 2025 Earnings Report

Day One Biopharmaceuticals logo
$6.86 -0.19 (-2.72%)
Closing price 03:59 PM Eastern
Extended Trading
$6.88 +0.02 (+0.25%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.28
Beat/Miss
N/A
One Year Ago EPS
N/A

Day One Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$38.20 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Day One Biopharmaceuticals Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, October 29, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Day One Biopharmaceuticals Earnings Headlines

Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $25.29
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.tc pixel
See More Day One Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals (NASDAQ:DAWN) (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development. The lead program, D1-B701, is a selective FGFR4 inhibitor designed to treat FGF19-driven hepatocellular carcinoma and other solid tumors. Additional programs include D1-H201, a selective HDAC6 inhibitor for certain hematologic malignancies, and D1-R199, a RET kinase inhibitor targeting RET fusion-positive cancers. Each program is supported by companion diagnostic strategies aimed at enriching patient populations and optimizing clinical outcomes.

Founded in 2017, Day One Biopharmaceuticals is headquartered in San Diego, California, and maintains research and development operations in both the United States and Asia. The company’s leadership team comprises professionals with extensive experience in oncology drug discovery, clinical development, regulatory affairs and commercial strategy. Day One collaborates with academic and industry partners to advance its pipeline and remains committed to addressing significant unmet needs in cancer therapeutics through scientifically rigorous and patient-focused innovation.

View Day One Biopharmaceuticals Profile

More Earnings Resources from MarketBeat